Intellia Therapeutics, Inc. (NTLA) earnings
NTLA earnings moved a median of -0.33% by the close. Quarterly and annual NTLA reports and results, each read against the price at its own news timestamp. Back to the NTLA overview →
29 measured NTLA earnings events.
Where these NTLA earnings landedvs 29 measured NTLA earnings reactions
| Middle 50% of NTLA earnings reactions | -2.92% to +2.56% |
|---|---|
| Median reaction (to close) | -0.33% |
| Measured reactions | 29 |
Point-in-time · zero look-ahead
Half of the 29 NTLA earnings events with a measured close landed between -2.92% and +2.56%; 45% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Intellia Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -3.63% | -0.33% | |
| Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates | Press release | +2.63% | +5.64% | |
| Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates | Press release | +1.19% | +1.65% | |
| Form 10-Q Intellia Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +3.98% | +2.56% | |
| Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates | Press release | +3.98% | +2.56% | |
| Form 10-K Intellia Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +1.00% | -1.36% | |
| Form 10-Q Intellia Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +4.06% | +4.50% | |
| Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates | Press release | +4.06% | +4.50% | |
| Form 10-Q Intellia Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -3.35% | -6.25% | |
| Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress | Press release | -2.09% | -0.09% | |
| Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates | Press release | +0.50% | -3.16% | |
| Form 10-Q Intellia Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +2.08% | -3.56% | |
| Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress | Press release | -5.48% | +5.34% | |
| Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates | Press release | -4.38% | -2.92% | |
| Form 10-K Intellia Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -6.72% | -1.75% | |
| Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2024 Earnings and Company Updates | Press release | -2.04% | -2.23% | |
| Form 10-Q Intellia Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -1.56% | +4.24% | |
| Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress | Press release | +1.17% | -1.24% | |
| Form 10-Q Intellia Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -0.36% | -4.20% | |
| Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress | Press release | -1.13% | +1.36% | |
| Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company Updates | Press release | -0.87% | -4.59% | |
| Form 10-Q Intellia Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +0.20% | -2.16% | |
| Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress | Press release | -3.71% | +0.93% | |
| Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates | Press release | -0.31% | +2.06% | |
| Form 10-K Intellia Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -0.30% | -2.32% | |
| Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates | Press release | -0.11% | +4.32% | |
| Form 10-Q Intellia Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -0.88% | -3.71% | |
| Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress | Press release | -5.39% | -12.42% | |
| Intellia Therapeutics to Present Updated Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis and Hold Conference Call to Discuss Third Quarter 2023 Earnings in November | Press release | +1.76% | +1.22% |
Keep exploring
More NTLA: analyst actions → · SEC filings → · NTLA overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Sage Therapeutics, Inc. (SAGE) | 951 | -0.14% | 41% |
| Geron Corporation (GERN) | 949 | -0.28% | 41% |
| Biohaven Ltd. Common Shares (BHVN) | 944 | -0.27% | 45% |
| GW PHARMACEUTICALS PLC AMERICA (GWPH) | 942 | -0.06% | 47% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.